NSAID celecoxib: a potent mitochondrial pro-oxidant cytotoxic agent sensitizing metastatic cancers and cancer stem cells to chemotherapy

Abstract

Intermittent hypoxia within tumor microenvironments causes pro-oxidative stress impairing oxidative phosphorylation (OxPhos) and increases mitochondrial production of reactive oxygen species (ROS). In primary tumors this provokes metabolic reprogramming of both tumor cells and cancer stem cells and emergence of highly metastatic cancer cells. Tumor reprogramming is initiated by activating nuclear respiratory factors and hypoxia-inducible factors in response to changes in oxygen and ROS levels. Hence, hypoxia-induced pro-oxidative stress drives invasion and metastasis. However, it is also the Achilles’ heel of metastatic cancer cells because pro-oxidative agents further overload the mitochondria and intracellular milieu with excessive ROS to trigger apoptosis, whereas antioxidant agents promote their survival and tumor progression. Herein lies the metastatic tumor cell sensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) and we and others have shown that the NSAID celecoxib exerts powerful pro-oxidative anticancer effects by directly targeting mitochondria to increase ROS production and trigger cancer cell death, including metastatic cancer cells and cancer stem cells. This review highlights the considerable benefits from appropriate NSAID use in humans against post-diagnosis metastatic tumors and the need to further develop their use as adjuvant therapy for advanced stage metastatic disease where they are already showing significantly improved clinical outcomes.

Keywords

Non-steroidal anti-inflammatory drug / celecoxib / metastasis / anticancer / mitocans / chemosensitizing / cancer stem cells / therapy

References

[1] Freitas M,Proenca T,Mota-Pinto A.Oxidative stress adaptation in aggressive prostate cancer may be counteracted by the reduction of glutathione reductase.FEBS Open Bio2012;2:119-28 PMCID:PMC3642126

[2] Nishikawa M.Reactive oxygen species in tumor metastasis.Cancer Lett2008;266:53-9

[3] Peiris-Pagès M,Sotgia F.Metastasis and oxidative stress: are antioxidants a metabolic driver of progression?.Cell Metab2015;22:956-8

[4] Piantadosi CA,Babiker A.Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1.Circ Res2008;103:1232-40 PMCID:PMC2694963

[5] Rodic S.Reactive oxygen species (ROS) are a key determinant of cancer's metabolic phenotype.Int J Cancer2018;142:440-8

[6] Wang J.Cancer cell killing via ROS: to increase or decrease, that is the question.Cancer Biol Ther2008;7:1875-84

[7] Rojo de la Vega M,Zhang DD.NRF2 and the hallmarks of cancer.Cancer Cell2018;34:21-43

[8] Toth RK.Strange bedfellows: nuclear factor, erythroid 2-Like 2 (Nrf2) and hypoxia-inducible factor 1 (HIF-1) in tumor hypoxia..Antioxidants (Basel)2017;6:pii: E27

[9] Athale J,MacGarvey NC,Welty-Wolf KE,Piantadosi CA.Nrf2 promotes alveolar mitochondrial biogenesis and resolution of lung injury in Staphylococcus aureus pneumonia in mice.Free Radic Biol Med2012;53:1584-94 PMCID:PMC3729022

[10] MacGarvey NC,Bartz RR,Withers CM,Piantadosi CA.Activation of mitochondrial biogenesis by heme oxygenase-1-mediated NF-E2-related factor-2 induction rescues mice from lethal Staphylococcus aureus sepsis.Am J Respir Crit Care Med2012;185:851-61 PMCID:PMC3360573

[11] Dominy JE.Mitochondrial biogenesis through activation of nuclear signaling proteins.Cold Spring Harb Perspect Biol2013;5:pii: a015008 PMCID:PMC3685894

[12] Cherry AD,Bartz RR.Peroxisome proliferator-activated receptor γ co-activator 1-α as a critical co-activator of the murine hepatic oxidative stress response and mitochondrial biogenesis in Staphylococcus aureus sepsis.J Biol Chem2014;289:41-52 PMCID:PMC3879563

[13] Scarpulla RC.Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator.Ann N Y Acad Sci2008;1147:321-34 PMCID:PMC2853241

[14] Ralph SJ,Neuzil J,Moreno-Sánchez R.The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy.Mol Aspects Med2010;31:145-70

[15] Handschin C.Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism.Endocr Rev2006;27:728-35

[16] Aquilano K,Pagliei B,Rotilio G.p53 orchestrates the PGC-1α-mediated antioxidant response upon mild redox and metabolic imbalance.Antioxid Redox Signal2013;18:386-99 PMCID:PMC3526895

[17] Yin W,Iwai M,Gao Y.Rapidly increased neuronal mitochondrial biogenesis after hypoxic-ischemic brain injury.Stroke2008;39:3057-63 PMCID:PMC2726706

[18] Gravel SP.Deciphering the dichotomous effects of PGC-1α on tumorigenesis and metastasis.Front Oncol2018;8:75 PMCID:PMC5876244

[19] LeBleu VS,Gonzalez Herrera KN,Pantel K,de Carvalho FM,Domingos Chinen LT,Asara JM.PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis.Nat Cell Biol2014;16:992-1003, 1-15

[20] LaGory EL,Taniguchi CM,Chi JT,Scott DA,Giaccia AJ.Suppression of PGC-1α is critical for reprogramming oxidative metabolism in renal cell carcinoma.Cell Rep2015;12:116-27 PMCID:PMC4518559

[21] Taguchi A,Celiktaş M,Wang H,Hanash SM.Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.Proteomics2014;14:2750-9 PMCID:PMC4403731

[22] Vazquez F,Chim H,Girnun G,Clish CB,Widlund HR,Puigserver P.PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress.Cancer Cell2013;23:287-301 PMCID:PMC3708305

[23] Choi HI,Park JS,Bae EH,Kim SW.PGC-1α attenuates hydrogen peroxide-induced apoptotic cell death by upregulating Nrf-2 via GSK3β inactivation mediated by activated p38 in HK-2 Cells.Sci Rep2017;7:4319 PMCID:PMC5489530

[24] Sen N,Das S.PGC-1α, a key modulator of p53, promotes cell survival upon metabolic stress.Mol Cell2011;44:621-34

[25] Popowich DA,Walsh CP,Rossi NB,Aalami OO.Regulation of reactive oxygen species by p53: implications for nitric oxide-mediated apoptosis.Am J Physiol Heart Circ Physiol2010;298:H2192-200 PMCID:PMC2886652

[26] Lisek K,Ciani Y,Del Sal G.Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells.Oncotarget2018;9:20508-23 PMCID:PMC5945496

[27] Clemons NJ,Duong CP.Inhibiting system xC- and glutathione biosynthesis - a potential Achilles' heel in mutant-p53 cancers.Mol Cell Oncol2017;4:e1344757 PMCID:PMC5644480

[28] Liu DS,Haupt S,House CM,Pearson HB,Read M,Haupt Y,Wiman KG,Phillips WA.Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation.Nat Commun2017;8:14844 PMCID:PMC5379068

[29] Chen D,Chu B,Chen Y,Gu W.NRF2 is a major target of ARF in p53-independent tumor suppression.Mol Cell2017;68:224-32

[30] Todoric J,Di Caro G,Wu X,Dhar D,Fagman JB,Umemura A,Kessler H,Goggins M,Diaz-Meco M,Karin M.Stress-activated NRF2-MDM2 cascade controls neoplastic progression in pancreas.Cancer Cell2017;32:824-39

[31] Komatsu M,Waguri S,Kobayashi A,Sou YS,Sakamoto A,Kim M,Iemura S,Ueno T,Motohashi H,Yamamoto M.The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1.Nat Cell Biol2010;12:213-23

[32] Kapuy O,Vellai T,Korcsmáros T.Systems-level feedbacks of NRF2 controlling autophagy upon oxidative stress response.Antioxidants (Basel)2018;7:pii: E39

[33] Li P,Shen L,Wu M,Shi D.Redox homeostasis protects mitochondria through accelerating ROS conversion to enhance hypoxia resistance in cancer cells.Sci Rep2016;6:22831 PMCID:PMC4783784

[34] Kim B.Mitochondrial dynamics altered by oxidative stress in cancer.Free Radic Res2016;50:1065-70

[35] Lo SC.PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to mitochondria.Exp Cell Res2008;314:1789-803 PMCID:PMC2409987

[36] Tian H,Di J,Chen F,Li L,Zheng J.Keap1: one stone kills three birds Nrf2, IKKβ and Bcl-2/Bcl-xL.Cancer Lett2012;325:26-34

[37] Giudice A,Turco MC.Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway by chemopreventive agents.Methods Mol Biol2010;647:37-74

[38] Dinkova-Kostova AT,Kostov RV.KEAP1 and done? Targeting the NRF2 pathway with sulforaphane.Trends Food Sci Technol2017;69:257-69

[39] Sihvola V.Keap1 as the redox sensor of the antioxidant response.Arch Biochem Biophys2017;617:94-100

[40] Jaramillo MC.The emerging role of the Nrf2-Keap1 signaling pathway in cancer.Genes Dev2013;27:2179-91 PMCID:PMC3814639

[41] Dinkova-Kostova AT,Cole RN,Wakabayashi N,Yamamoto M.Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants.Proc Natl Acad Sci U S A2002;99:11908-13 PMCID:PMC129367

[42] Dinkova-Kostova AT,Canning P.Keap1, the cysteine-based mammalian intracellular sensor for electrophiles and oxidants.Arch Biochem Biophys2017;617:84-93 PMCID:PMC5339396

[43] Canning P.New strategies to inhibit KEAP1 and the Cul3-based E3 ubiquitin ligases.Biochem Soc Trans2014;42:103-7 PMCID:PMC3935762

[44] Leinonen HM,Pölönen P,Levonen AL.Dysregulation of the Keap1-Nrf2 pathway in cancer.Biochem Soc Trans2015;43:645-9

[45] Cancer Genome Atlas Research Network..Comprehensive genomic characterization of squamous cell lung cancers.Nature2012;489:519-25 PMCID:PMC3466113

[46] Hanada N,Zhou Q,Sun R,Ishiguro A,Mimura J,Fukuda S.Methylation of the KEAP1 gene promoter region in human colorectal cancer.BMC Cancer2012;12:66 PMCID:PMC3296656

[47] Satoh H,Takai J,Yamamoto M.Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis.Cancer Res2013;73:4158-68

[48] Tao S,Chapman E,Zhang DD.The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer.Mol Carcinog2018;57:182-92

[49] Tochhawng L,Pervaiz S.Redox regulation of cancer cell migration and invasion.Mitochondrion2013;13:246-53

[50] Jeddi F,Sadeghi MR,Samadi N.Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/promotion and chemoresistance.DNA Repair (Amst)2017;54:13-21

[51] Sadeghi MR,Soozangar N,Samadi N.The role of Nrf2-Keap1 axis in colorectal cancer, progression, and chemoresistance.Tumour Biol2017;39:1010428317705510

[52] Wang H,Long M,Zhang L,Zheng Y,Wang Y,Li W,Tong Q,Fang F,Ouyang Q,Yu S.NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis.Sci Transl Med2016;8:334ra51

[53] Zhang C,Bao QC,Guo TK,Xu LL,Bian JL,Sun HP,You QD.NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction.Oncotarget2016;7:73593-606

[54] DeNicola GM,Humpton TJ,Wei C,Mangal D,Yeo CJ,Scrimieri F,Hruban RH,Kern SE,Tuveson DA.Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.Nature2011;475:106-9 PMCID:PMC3404470

[55] Ji L,Gao P,Zhang DD,Jiang T.Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer.PLoS One2013;8:e63404 PMCID:PMC3646742

[56] Jeddi F,Sadeghi MR,Shirmohamadi M,Samadi N.Nrf2 overexpression is associated with P-glycoprotein upregulation in gastric cancer.Biomed Pharmacother2018;97:286-92

[57] Xu B,Strom J,Chen QM.Myocardial ischemic reperfusion induces de novo Nrf2 protein translation.Biochim Biophys Acta2014;1842:1638-47 PMCID:PMC4968415

[58] Hawkins KE,Delhove JM,Fernandez E,Whiteford JR,Bolanos JP,Waddington SN.NRF2 orchestrates the metabolic shift during induced pluripotent stem cell reprogramming.Cell Rep2016;14:1883-91 PMCID:PMC4785773

[59] Chang CW,Tsay YG,Chen YJ,Hung KF,Huang TY,Lee TC.ROS-independent ER stress-mediated NRF2 activation promotes warburg effect to maintain stemness-associated properties of cancer-initiating cells.Cell Death Dis2018;9:194 PMCID:PMC5833380

[60] Malec V,Li S,Seeger W.HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells.Free Radic Biol Med2010;48:1626-35

[61] Philip B,Moreno-Sánchez R.HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression.Carcinogenesis2013;34:1699-707

[62] Niecknig H,Reyes BD,Fandrey J.Role of reactive oxygen species in the regulation of HIF-1 by prolyl hydroxylase 2 under mild hypoxia.Free Radic Res2012;46:705-17

[63] Semenza GL.Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype.EMBO J2017;36:252-9 PMCID:PMC5286373

[64] Marín-Hernández A,Ralph SJ,Moreno-Sánchez R.HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms.Mini Rev Med Chem2009;9:1084-101

[65] Okamoto A,Tanaka H,Iwai T,Matsuo Y,Takenaga K,Hirota K.HIF-1-mediated suppression of mitochondria electron transport chain function confers resistance to lidocaine-induced cell death.Sci Rep2017;7:3816 PMCID:PMC5476559

[66] Zhang H,Fukuda R,Krishnamachary B,Dang CV.HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity.Cancer Cell2007;11:407-20

[67] Fukuda R,Kim JW,Dang CV.HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells.Cell2007;129:111-22

[68] Harris IS,Inoue S,Gorrini C,Yung KY,Knobbe-Thomsen CB,Elia A,Cescon DW,Brüstle A,Mason JM,Yamamoto K,Berman HK,Done SJ,Lam CW.Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression.Cancer Cell2015;27:211-22

[69] Piskounova E,Murphy MM,Huddlestun SE,Leitch AM,DeBerardinis RJ.Oxidative stress inhibits distant metastasis by human melanoma cells.Nature2015;527:186-91 PMCID:PMC4644103

[70] Zhang L,Liu J,Hu Z.Protective effect of N-acetylcysteine (NAC) on renal ischemia/reperfusion injury through Nrf2 signaling pathway.J Recept Signal Transduct Res2014;34:396-400

[71] Ji L,Zhang XD,Bai H,Zhao HL,Hai CX.N-acetylcysteine attenuates phosgene-induced acute lung injury via up-regulation of Nrf2 expression.Inhal Toxicol2010;22:535-42

[72] Wang LL,Yan CY,Hou JQ,Lv JX.N-acetylcysteine ameliorates prostatitis via miR-141 regulating Keap1/Nrf2 signaling.Inflammation2016;39:938-47

[73] Moss RW.Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants?.Integr Cancer Ther2006;5:63-82

[74] Chio IIC.ROS in cancer: the burning question.Trends Mol Med2017;23:411-29 PMCID:PMC5462452

[75] Hiramoto K,Suzuki T,Pi J,Yamamoto M.Myeloid lineage-specific deletion of antioxidant system enhances tumor metastasis..Cancer Prev Res (Phila)2014;7:835-44

[76] Le Gal K,Wiel C,Akula MK,Dalin MG,Lindahl P,Bergo MO.Antioxidants can increase melanoma metastasis in mice.Sci Transl Med2015;7:308re8

[77] Cairns RA,Mak TW.Regulation of cancer cell metabolism.Nat Rev Cancer2011;11:85-95

[78] Sayin VI,Larsson E,Lindahl P.Antioxidants accelerate lung cancer progression in mice.Sci Transl Med2014;6:221ra15

[79] Zhang Z,Taheri S,Shi H.Hypoxia-inducible factor 1 contributes to N-acetylcysteine's protection in stroke.Free Radic Biol Med2014;68:8-21 PMCID:PMC3943875

[80] Haddad JJ,Land SC.Antioxidant/pro-oxidant equilibrium regulates HIF-1alpha and NF-kappa B redox sensitivity.Evidence for inhibition by glutathione oxidation in alveolar epithelial cells. J Biol Chem2000;275:21130-9

[81] Jin WS,Shen ZF,Zhang WK.Regulation of hypoxia inducible factor-1α expression by the alteration of redox status in HepG2 cells.J Exp Clin Cancer Res2011;30:61 PMCID:PMC3113749

[82] Aruoma OI,Hoey BM.The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid.Free Radic Biol Med1989;6:593-7

[83] Samuni Y,Dean OM.The chemistry and biological activities of N-acetylcysteine.Biochim Biophys Acta2013;1830:4117-29

[84] Ezeriņa D,Hanaoka K,Dick TP.N-Acetyl cysteine functions as a fast-acting antioxidant by triggering intracellular H2S and sulfane sulfur production.Cell Chem Biol2018;25:447-59

[85] Kim KY,Choi I.N-acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity.J Biol Chem2001;276:40591-8

[86] Hayes JD.Epigenetic control of NRF2-directed cellular antioxidant status in dictating life-death decisions.Mol Cell2017;68:5-7

[87] Pehar M,Sharma DR,Comte-Walters S,Vargas MR.Changes in protein expression and lysine acetylation induced by decreased glutathione levels in astrocytes.Mol Cell Proteomics2016;15:493-505 PMCID:PMC4739669

[88] Sceneay J,Chen A,Bowtell DD.The antioxidant N-acetylcysteine prevents HIF-1 stabilization under hypoxia in vitro but does not affect tumorigenesis in multiple breast cancer models in vivo.PLoS One2013;8:e66388 PMCID:PMC3688768

[89] Gao P,Dinavahi R,Xiang Y,Bhujwalla ZM,Cheng L,Lee LA,Dang CV.HIF-dependent antitumorigenic effect of antioxidants in vivo.Cancer Cell2007;12:230-8 PMCID:PMC2084208

[90] Zhao T,Morinibu A,Shinomiya K,Yoshimura M,Hiraoka M.HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs.Sci Rep2014;4:3793 PMCID:PMC3899644

[91] Albini A,Giunciuglio D,Balansky R.Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine.Int J Cancer1995;61:121-9

[92] Li L,Qi C,Fang Y,Feng J,Ning W.Intermittent hypoxia promotes melanoma lung metastasis via oxidative stress and inflammation responses in a mouse model of obstructive sleep apnea.Respir Res2018;19:28 PMCID:PMC5809953

[93] Chen A,Gödde N,Ham S,Humbert PO.Intermittent hypoxia induces a metastatic phenotype in breast cancer.Oncogene2018;37:4214-25

[94] Zhu H,Trush MA.Nrf2 deficiency promotes melanoma growth and lung metastasis.React Oxyg Species (Apex)2016;2:308-14

[95] Süleyman H,Karagöz Y.Anti-inflammatory and side effects of cyclooxygenase inhibitors.Pharmacol Rep2007;59:247-58

[96] Patrignani P.Cyclooxygenase inhibitors: from pharmacology to clinical read-outs.Biochim Biophys Acta2015;1851:422-32

[97] Tsioulias GJ,Rigas B.NSAIDs and colorectal cancer control: promise and challenges.Curr Pharmacol Rep2015;1:295-301 PMCID:PMC4683110

[98] Steinbach G,Phillips RK,Hawk E,Wakabayashi N,Shen Y,Su LK,Godio L,Rodriguez-Bigas MA,King KL,Abbruzzese J,Hittelman WN,Sherman JW.The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.N Engl J Med2000;342:1946-52

[99] Arber N,Spicak J,Dite P,Zavoral M,Gerletti P,Rosenstein RB,Bhadra P,Wittes J,Solomon SD.Celecoxib for the prevention of colorectal adenomatous polyps.N Engl J Med2006;355:885-95

[100] Arber N,Rácz I,Breazna A,Lechuga MJ,Rosenstein RB,Levin B.Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial.Am J Gastroenterol2011;106:1135-46

[101] Burke CA,Samadder NJ,Cohen A.Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.BMC Gastroenterol2016;16:87 PMCID:PMC4969736

[102] Lynch PM,Phillips R,Slack R,Liu J,Sinicrope FA,Half E,Latchford A,Ross WA,Hasson H,Hawk E.An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis.Gut2016;65:286-95

[103] Burn J.The role of aspirin in preventing colorectal cancer.Br Med Bull2016;119:17-24

[104] Emilsson L,Bretthauer M,Buring JE,Adami HO,Gaziano MJ.Systematic review with meta-analysis: the comparative effectiveness of aspirin vs.screening for colorectal cancer prevention. Aliment Pharmacol Ther2017;45:193-204

[105] Paleari L,Clavarezza M,Cuzick J.PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer..A systematic review and meta-analysis of epidemiological studies. Clin Oncol (R Coll Radiol)2016;28:317-26

[106] Liao X,Nishihara R,Kuchiba A,Imamura Y,Baba Y,Sun R,Meyerhardt JA,Fuchs CS,Ogino S.Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.N Engl J Med2012;367:1596-606 PMCID:PMC3532946

[107] Alfonso L,Spitale RC.Molecular targets of aspirin and cancer prevention.Br J Cancer2014;111:61-7 PMCID:PMC4090734

[108] Dunlap T,Wijewickrama GT,Vanni M,Luo J.Quinone-induced activation of Keap1/Nrf2 signaling by aspirin prodrugs masquerading as nitric oxide.Chem Res Toxicol2012;25:2725-36 PMCID:PMC3896098

[109] Jian Z,Yi X,Zhang Q,Wang G,Li C.Aspirin induces Nrf2-mediated transcriptional activation of haem oxygenase-1 in protection of human melanocytes from H2 O2 -induced oxidative stress.J Cell Mol Med2016;20:1307-18 PMCID:PMC4929306

[110] Satoh T.Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate.F1000Res2017;6:2138 PMCID:PMC5730864

[111] Hua X,Burnett-Hartman AN,Hardikar S,Kocarnik JM,Lindor NM,Newcomb PA.Timing of aspirin and other nonsteroidal anti-inflammatory drug use among patients with colorectal cancer in relation to tumor markers and survival.J Clin Oncol2017;35:2806-13 PMCID:PMC5562174

[112] Kuo CN,Huang YW,Chang WC.Association between nonsteroidal anti-inflammatory drugs and colorectal cancer: a population-based case-control study.Cancer Epidemiol Biomarkers Prev2018;27:737-45

[113] Elwood PC,Pickering JE,Weightman AL,Kelson M.Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies.PLoS One2016;11:e0152402 PMCID:PMC4838306

[114] Chubak J,Williams SB,Burda BU,Anderson ML.Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. preventive services task force.Ann Intern Med2016;164:814-25

[115] Huang XZ,Wu J,Wu CC,Sun SS.Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: a dose-response meta-analysis.Oncotarget2017;8:4781-95

[116] Li P,Zhang H,Xu J,Xia D,Cai J.Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.Gut2015;64:1419-25

[117] Usman MW,Cheng H,Liu P.Chemopreventive effects of aspirin at a glance.Biochim Biophys Acta2015;1855:254-63

[118] Veettil SK,Ching SM,Phisalprapa P.Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials.BMC Cancer2017;17:763 PMCID:PMC5686945

[119] Johnson CC,Rolnick S,Alford SH.Influence of NSAID use among colorectal cancer survivors on cancer outcomes.Am J Clin Oncol2017;40:370-4 PMCID:PMC4465051

[120] Zhao X,Li H.NSAIDs use and reduced metastasis in cancer patients: results from a meta-analysis.Sci Rep2017;7:1875 PMCID:PMC5431951

[121] Moris D,Spartalis E.The role of NSAIDs in breast cancer prevention and relapse: current evidence and future perspectives.Breast Care (Basel)2016;11:339-44 PMCID:PMC5122986

[122] Veitonmäki T,Talala K,Tammela T.Non-steroidal anti-inflammatory drugs and cancer death in the finnish prostate cancer screening trial.PLoS One2016;11:e0153413 PMCID:PMC4839624

[123] Zhou CK,Liao LM,Abnet CC,Cook MB.Do aspirin and other NSAIDs confer a survival benefit in men diagnosed with prostate cancer? A pooled analysis of NIH-AARP and PLCO cohorts.Cancer Prev Res (Phila)2017;10:410-20 PMCID:PMC5516895

[124] Rachidi S,Li H,Li Z.Postdiagnosis aspirin use and overall survival in patients with melanoma.J Am Acad Dermatol2018;78:949-56

[125] van Staalduinen J,Reimers M,van Herk-Sukel MP,de Steur WO,van de Velde CJ.The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients.Br J Cancer2016;114:1053-9 PMCID:PMC4984910

[126] Frouws MA,Langley RE,van Herk-Sukel MP,Putter H,Bonsing BA,Portielje JE.Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study.Br J Cancer2017;116:405-13 PMCID:PMC5294482

[127] Matsuo K,Yoshihara K,Kakuda M,Moeini A,Garcia-Sayre J,Enomoto T,Roman LD.Association of low-dose aspirin and survival of women with endometrial cancer.Obstet Gynecol2016;128:127-37

[128] Zhang D,Xi Y.Can aspirin reduce the risk of endometrial cancer? A systematic review and meta-analysis of observational studies.Int J Gynecol Cancer2016;26:1111-20

[129] Spence AD,Johnston BT,Hughes CM,Cardwell CR.Low-dose aspirin use does not increase survival in 2 independent population-based cohorts of patients with esophageal or gastric cancer.Gastroenterology2018;154:849-60

[130] Dixon SC,Wentzensen N,Beeghly-Fadiel A,Moysich KB,Risch HA,Doherty JA,Goodman MT,Ness RB,Jensen A,Høgdall E,Cramer DW,Poole EM,Paddock LE,Ziogas A,Gayther SA,Gentry-Maharaj A,Wu AH,Webb PM.Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium..Br J Cancer2017;116:1223-8 PMCID:PMC5418444

[131] Brasky TM,Cohn DE,Mutch DG,Thaker PH,Moore RG,Guntupalli SR,Nagel CI,Pearl ML,Park KJ,Brinton LA.Nonsteroidal anti-inflammatory drugs and endometrial carcinoma mortality and recurrence.J Natl Cancer Inst2017;109:1-10 PMCID:PMC5161320

[132] Verdoodt F,Friis S.Influence of aspirin and non-aspirin NSAID use on ovarian and endometrial cancer: summary of epidemiologic evidence of cancer risk and prognosis.Maturitas2017;100:1-7

[133] Gurpinar E,Piazza GA.NSAIDs inhibit tumorigenesis, but how?.Clin Cancer Res2014;20:1104-13 PMCID:PMC3947450

[134] Panieri E.ROS homeostasis and metabolism: a dangerous liason in cancer cells.Cell Death Dis2016;7:e2253 PMCID:PMC5143371

[135] Vander Heiden MG.Understanding the intersections between metabolism and cancer biology.Cell2017;168:657-69 PMCID:PMC5329766

[136] Liu J.Increased oxidative stress as a selective anticancer therapy.Oxid Med Cell Longev2015;2015:294303 PMCID:PMC4529973

[137] Edelman MJ,Hodgson L,Baggstrom MQ,Gajra A,Reckamp KL,Schiller JH,Friedman PN,Milne G,Stinchcombe TE.Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non-small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (Alliance)..J Clin Oncol2017;35:2184-92 PMCID:PMC5493050

[138] Groen HJ,Vincent A,van Putten JW,Dalesio O,Smit HJ,Hiltermann TJ,Schramel FM.Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.J Clin Oncol2011;29:4320-6

[139] Patel MI,Du B,Yang P,Cordon-Cardo C,Dannenberg AJ.Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.Clin Cancer Res2005;11:1999-2007

[140] Williams CS,Sheng H,Shao J.Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models.Cancer Res2000;60:6045-51

[141] Xu B,Yang J,Zhang Y.Celecoxib induces apoptosis but up-regulates VEGF via endoplasmic reticulum stress in human colorectal cancer in vitro and in vivo.Cancer Chemother Pharmacol2016;77:797-806

[142] Sobolewski C,Legrand N,Cerella C,Chateauvieux S,Yoon AY,Dicato M.2,5-Dimethyl-celecoxib inhibits cell cycle progression and induces apoptosis in human leukemia cells.J Pharmacol Exp Ther2015;355:308-28

[143] Schönthal AH.Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy.Neurosurg Focus2006;20:E21

[144] Pyrko P,Liu YT,Xiong W,Uddin J,Mircheff AK,Louie SG,Schönthal AH.Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib.Mol Cancer Ther2007;6:1262-75

[145] Schiffmann S,Wobst I,Corban-Wilhelm H,Geisslinger G.The anti-proliferative potency of celecoxib is not a class effect of coxibs.Biochem Pharmacol2008;76:179-87

[146] Waskewich C,Li H,Goldenberg DM.Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.Cancer Res2002;62:2029-33

[147] Jendrossek V,Belka C.Celecoxib activates a novel mitochondrial apoptosis signaling pathway.FASEB J2003;17:1547-9

[148] Zhu J,Lin HP,Yan S,Chen CS.Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents.J Natl Cancer Inst2002;94:1745-57

[149] Bosch R,Céspedes MV,Pavón Má,Sierra J,Casanova I.A novel inhibitor of focal adhesion signaling induces caspase-independent cell death in diffuse large B-cell lymphoma.Blood2011;118:4411-20

[150] Casanova I,Lasa A,Céspedes MV,Nomdedéu JF,Sierra J.A celecoxib derivative inhibits focal adhesion signaling and induces caspase-8-dependent apoptosis in human acute myeloid leukemia cells.Int J Cancer2008;123:217-26

[151] Bosch R,Dieguez-Gonzalez R,Gallardo A,Gra-ena A,Casanova I.A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B-cell lymphoma with central nervous system involvement.Haematologica2013;98:1242-9 PMCID:PMC3729905

[152] Ralph SJ,Rodríguez-Enríquez S,Ralph RK.Hitting the bull's-eye in metastatic cancers-NSAIDs elevate ROS in mitochondria, inducing malignant cell death.Pharmaceuticals (Basel)2015;8:62-106 PMCID:PMC4381202

[153] Pritchard R,Pacheco-Velázquez SC,Moreno-Sánchez R.Celecoxib inhibits mitochondrial O2 consumption, promoting ROS dependent death of murine and human metastatic cancer cells via the apoptotic signalling pathway.Biochem Pharmacol2018;154:318-34

[154] Pacheco-Velázquez SC,Hernández-Reséndiz I,Moreno-Sánchez R.Energy metabolism drugs block triple negative breast metastatic cancer cell phenotype.Mol Pharm2018;15:2151-64

[155] Huang C,Liu H,Song X,He N,Wang Y,Dong Q.Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity.Oncotarget2017;8:115254-69 PMCID:PMC5777769

[156] Kurtova AV,Mo Q,Krasnow R,Chen F,Lay E,Chan KS.Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance.Nature2015;517:209-13 PMCID:PMC4465385

[157] Wang JS,Kang HC,Huang KC.Celecoxib induces heme oxygenase-1 expression in macrophages and vascular smooth muscle cells via ROS-dependent signaling pathway.Naunyn Schmiedebergs Arch Pharmacol2011;383:159-68

[158] Hamdulay SS,Birdsey GM,Dumont O,Haskard DO,Mason JC.Celecoxib activates PI-3K/Akt and mitochondrial redox signaling to enhance heme oxygenase-1-mediated anti-inflammatory activity in vascular endothelium.Free Radic Biol Med2010;48:1013-23

[159] Al-Rashed F,Lang M,Bauer A,Haskard DO,Boyle JJ,Wheeler-Jones CP.Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2 signalling.Sci Rep2018;8:6271 PMCID:PMC5908847

[160] Irie T,Tsuji S,Ishii S,Egawa S,Nishida T,Iijima H,Takehara T,Hayashi N.Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma.Int J Cancer2007;121:878-83

[161] Zhao S,Bian H,Zhao F.Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.Cancer Invest2009;27:636-40

[162] Sadhu SS,Averineni RK,Yang Y.In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.Melanoma Res2016;26:572-9

[163] van Wijngaarden J,van Rossum G,Hoekman K,van der Pol MA,van Hinsbergh VW.Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.Eur J Cancer2007;43:433-42

[164] Angelini A,Di Febbo C,Cuccurullo F.Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs.Oncol Rep2008;20:731-5

[165] Fantappiè O,Lasagna N,Tessitore L.P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines.Cancer Res2007;67:4915-23

[166] Hiľovská L,Fedoročko P.Potency of non-steroidal anti-inflammatory drugs in chemotherapy.Mol Clin Oncol2015;3:3-12 PMCID:PMC4251142

[167] Moreno-Sánchez R,Vásquez C,Silveira LH.Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart.Biochem Pharmacol1999;57:743-52

[168] Jin CH,Chen JM,Liu XM,Xing LQ.Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer.J Int Med Res2011;39:2129-40

[169] Debucquoy A,Goethals L,Van Cutsem E,Penninckx F,McBride WH.Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer.Radiother Oncol2009;93:273-8

[170] Lin EH,Crane CC,Skibber J,Vadhan SR,Ayers GD,Brown T,Janjan N.Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?.Am J Clin Oncol2006;29:232-9

[171] Lin EH, Kim EY, Wang L, Fong C, Shankaran V, Wu X. ADAPT therapy vs capecitabine bevacizumab in stage IV colorectal cancer: pooled 10-year survival experience and a phase II study update. Available from: http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.e15046. [Last accessed on 12 Sep 2018]

[172] Lin EH, Patel SA, Chou J, Kim EY, Shankaran V, Coveler AL, Harris WP, Park JO, Fichera A, Mann GN, Chiorean EG, Pritchard CC, Sinanan M, Upton M, Storer B, Yeung RS, Li L. A phase II trial of maintenance ADAPT therapy targeting colon cancer stem cells in patients with metastatic colorectal cancer. Available from: http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.tps3650. [Last accessed on 12 Sep 2018]

[173] Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Denkert C, Murray E, Grieve R, Coleman R, Schmidt M, Klare P, Rezai M, Rautenberg B, Klutinus N, Rhein U, Mousa K, Ricardo-Vitorino S, von Minckwitz G, Bliss J. A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial). Available from: http://cancerres.aacrjournals.org/content/78/4_Supplement/GS3-03. [Last accessed on 12 Sep 2018]

[174] Zhou YY,Zeng FJ.Clinical Profile of cyclooxygenase-2 inhibitors in treating non-small cell lung cancer: a meta-analysis of nine randomized clinical trials.PLoS One2016;11:e0151939 PMCID:PMC4805232

[175] James ND,Clarke NW,Dearnaley DP,Ritchie AWS,Parker CC,Wallace J,Lydon A.Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: survival results from STAMPEDE (NCT00268476)..Clin Adv Hematol Oncol2016;14:11-3